[Cytel Whitepaper] How Can RWE Drive Oncology Drug Development?

June 24, 2021

Cytel has published a whitepaper detailing how real world evidence (RWE) can be used in cancer drug development, from preclinical studies to clinical trials and market access analyses. Oncology research poses a unique set of challenges and understanding how to overcome these barriers is critical for success.

“Challenges commonly faced by clinical development in oncology make methods involving real world evidence prized mechanisms for optimizing trial design. As Real World Evidence (RWE) in Oncology drug development grows, stay on top of the latest insights through Cytel’s new e-book. This e-book provides an overview of RWE uses for regulatory submission, providing an introduction to techniques and methods that might seem unfamiliar to those who work on Phase 1, 2 and 3 clinical studies.” Access the whitepaper here.

(Source: Cytel, 2021)

Share This Story!